Tyrosine kinase inhibitor resistance in de novo BCR::ABL1-positive BCP-ALL beyond kinase domain mutations
Blood Adv. 2024 Feb 22:bloodadvances.2023012162. doi: 10.1182/bloodadvances.2023012162. Online ahead of print.ABSTRACTA better understanding of ABL1-kinase domain mutation-independent causes of tyrosine kinase inhibitor (TKI) resistance is needed for BCR::ABL1-positive B-cell precursor acute lymphoblastic leukemia (BCP-ALL). While TKIs have dramatically improved outcomes, a subset of patients still experiences relapsed or refractory disease. We aimed to identify potential biomarkers for intrinsic TKI resistance at diagnosis in 32 pediatric and 19 adult BCR::ABL1-positive BCP-ALL samples. Reduced ex vivo imatinib sensitivit...
Source: Adv Data - February 22, 2024 Category: Epidemiology Authors: Inge van Outersterp Judith M Boer Cesca Van De Ven Caitlin Ej Reichert Aur élie Boeree Brian Kruisinga Hester A de Groot-Kruseman Gabriele Escherich Aniko Sijs-Szabo Anita W Rijneveld Monique L den Boer Source Type: research
Multi-target rational design and synthesis of novel diphenyl-tethered pyrazolopyrimidines targeting EGFR and topoisomerase II with potential DNA intercalation and apoptosis induction
Bioorg Chem. 2024 Feb 17;145:107223. doi: 10.1016/j.bioorg.2024.107223. Online ahead of print.ABSTRACTHerein, we envisioned the design and synthesis of novel pyrazolopyrimidines (confirmed by elemental analysis, 1H and 13C NMR, and mass spectra) as multitarget-directed drug candidates acting as EGFR/TOPO II inhibitors, DNA intercalators, and apoptosis inducers. The target diphenyl-tethered pyrazolopyrimidines were synthesized starting from the reaction of phenyl hydrazine and ethoxymethylenemalononitrile to give aminopyrazole-carbonitrile 2. The latter hydrolysis with NaOH and subsequent reaction with 4-chlorobenzaldhyde a...
Source: Bioorganic Chemistry - February 22, 2024 Category: Chemistry Authors: Ahmed A Gaber Ayman Abo Elmaaty Marwa Sharaky Aliaa A Mosa Abdullah Yahya Abdullah Alzahrani Saad Shaaban Wagdy M Eldehna Ahmed A Al-Karmalawy Source Type: research
Establishment and characterization of NCC-DFSP5-C1: a novel patient-derived dermatofibrosarcoma protuberans cell line
AbstractDermatofibrosarcoma protuberans (DFSP) is the most prevalent dermal sarcoma, characterized by the presence of the fusion of the collagen type I alpha 1 (COL1A1) gene with the platelet-derived growth factor beta chain (PDGFB) gene. Although PDGF receptor inhibitor imatinib mesylate was approved for the treating patients with unresectable or metastatic DFSP, disease progression was shown in 9.2% of the patients. Therefore, developing novel therapeutic strategies is crucial for improving the prognosis of DFSP. Patient-derived cell lines play a vital role in preclinical studies; however, only a limited number of DFSP c...
Source: Human Cell - February 19, 2024 Category: Cytology Source Type: research
Clinical activity of transforming growth factor- β inhibitor vactosertib in combination with imatinib in desmoid tumors: a multicenter phase Ib/II study
CONCLUSIONS: Vactosertib and imatinib combination was well-tolerated, with promising clinical activity in patients with progressive, locally advanced desmoid tumors. This is the first study investigating a novel target agent, a TGF-β inhibitor, in this rare and difficult-to-treat desmoid tumor.PMID:38363333 | DOI:10.1158/1078-0432.CCR-23-2823 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - February 16, 2024 Category: Cancer & Oncology Authors: Jin-Hee Ahn Jeeyun Lee Changhee Park Seung-Hoon Beom Seung Hyun Kim Young Han Lee Kum-Hee Yun Jeong Eun Kim Wooyeol Baek Yoon Dae Han Sang Kyum Kim Hyang Joo Ryu Inkyung Jung JooHee Lee Hong In Yoon Hyo Song Kim Source Type: research
Radiofrequency ablation vs. hepatectomy for liver metastases from gastrointestinal stromal tumors
In conclusion, hepatectomy combined with TKI therapy improved prognosis for patients with liver metastases to a greater extent than RFA combined with TKI therapy. For this type of patient, hepatectomy may be a preferable option.PMID:38362234 | PMC:PMC10867732 | DOI:10.3892/ol.2024.14266 (Source: Oncology Letters)
Source: Oncology Letters - February 16, 2024 Category: Cancer & Oncology Authors: Yi Zeng Yudong Ling Xiaojiang Chen Chao Ding Yukai Jin Shoucheng Feng Zhenchong Chen Jianrong Guo Haibo Qiu Source Type: research
Occurrence of Existing BCR-ABL Baseline Mutations and Associated Haplotype (NmR) Among CML Patients with Diverse IM Response: A Hospital-based Study from North-East India
This study was conducted to investigate the potential role of three significant SNPs in CML progression due to IM resistance. During the study period from 2018 to 2022 (48 months), the blood samples from 219 Reverse transcriptase-PCR-confirmed CML patients following RNA extraction and cDNA preparation were subjected to M351T, E255K, and Y253H mutation analysis by PCR-RFLP. After agarose gel visualization, the samples were subjected to Sanger sequencing to confirm the nucleotide change at the polymorphic loci. The wild-type genotype of all three ABL1 SNPs under investigation exhibits a significant reduction in frequency amo...
Source: Biochemical Genetics - February 16, 2024 Category: Genetics & Stem Cells Authors: Gautam Hazarika Manash Jyoti Kalita Partha Pratim Das Simanta Kalita Kalpajit Dutta Lipika Lahkar Anjanjyoti Rajkonwar Mohammed Ghaznavi Idris Vinotsale Khamo Giriraj Kusre Subhash Medhi Source Type: research
Clinical activity of transforming growth factor- β inhibitor vactosertib in combination with imatinib in desmoid tumors: a multicenter phase Ib/II study
CONCLUSIONS: Vactosertib and imatinib combination was well-tolerated, with promising clinical activity in patients with progressive, locally advanced desmoid tumors. This is the first study investigating a novel target agent, a TGF-β inhibitor, in this rare and difficult-to-treat desmoid tumor.PMID:38363333 | DOI:10.1158/1078-0432.CCR-23-2823 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - February 16, 2024 Category: Cancer & Oncology Authors: Jin-Hee Ahn Jeeyun Lee Changhee Park Seung-Hoon Beom Seung Hyun Kim Young Han Lee Kum-Hee Yun Jeong Eun Kim Wooyeol Baek Yoon Dae Han Sang Kyum Kim Hyang Joo Ryu Inkyung Jung JooHee Lee Hong In Yoon Hyo Song Kim Source Type: research
Radiofrequency ablation vs. hepatectomy for liver metastases from gastrointestinal stromal tumors
In conclusion, hepatectomy combined with TKI therapy improved prognosis for patients with liver metastases to a greater extent than RFA combined with TKI therapy. For this type of patient, hepatectomy may be a preferable option.PMID:38362234 | PMC:PMC10867732 | DOI:10.3892/ol.2024.14266 (Source: Oncology Letters)
Source: Oncology Letters - February 16, 2024 Category: Cancer & Oncology Authors: Yi Zeng Yudong Ling Xiaojiang Chen Chao Ding Yukai Jin Shoucheng Feng Zhenchong Chen Jianrong Guo Haibo Qiu Source Type: research
Occurrence of Existing BCR-ABL Baseline Mutations and Associated Haplotype (NmR) Among CML Patients with Diverse IM Response: A Hospital-based Study from North-East India
This study was conducted to investigate the potential role of three significant SNPs in CML progression due to IM resistance. During the study period from 2018 to 2022 (48 months), the blood samples from 219 Reverse transcriptase-PCR-confirmed CML patients following RNA extraction and cDNA preparation were subjected to M351T, E255K, and Y253H mutation analysis by PCR-RFLP. After agarose gel visualization, the samples were subjected to Sanger sequencing to confirm the nucleotide change at the polymorphic loci. The wild-type genotype of all three ABL1 SNPs under investigation exhibits a significant reduction in frequency amo...
Source: Biochemical Genetics - February 16, 2024 Category: Genetics & Stem Cells Authors: Gautam Hazarika Manash Jyoti Kalita Partha Pratim Das Simanta Kalita Kalpajit Dutta Lipika Lahkar Anjanjyoti Rajkonwar Mohammed Ghaznavi Idris Vinotsale Khamo Giriraj Kusre Subhash Medhi Source Type: research
Clinical activity of transforming growth factor- β inhibitor vactosertib in combination with imatinib in desmoid tumors: a multicenter phase Ib/II study
CONCLUSIONS: Vactosertib and imatinib combination was well-tolerated, with promising clinical activity in patients with progressive, locally advanced desmoid tumors. This is the first study investigating a novel target agent, a TGF-β inhibitor, in this rare and difficult-to-treat desmoid tumor.PMID:38363333 | DOI:10.1158/1078-0432.CCR-23-2823 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - February 16, 2024 Category: Cancer & Oncology Authors: Jin-Hee Ahn Jeeyun Lee Changhee Park Seung-Hoon Beom Seung Hyun Kim Young Han Lee Kum-Hee Yun Jeong Eun Kim Wooyeol Baek Yoon Dae Han Sang Kyum Kim Hyang Joo Ryu Inkyung Jung JooHee Lee Hong In Yoon Hyo Song Kim Source Type: research
Radiofrequency ablation vs. hepatectomy for liver metastases from gastrointestinal stromal tumors
In conclusion, hepatectomy combined with TKI therapy improved prognosis for patients with liver metastases to a greater extent than RFA combined with TKI therapy. For this type of patient, hepatectomy may be a preferable option.PMID:38362234 | PMC:PMC10867732 | DOI:10.3892/ol.2024.14266 (Source: Oncology Letters)
Source: Oncology Letters - February 16, 2024 Category: Cancer & Oncology Authors: Yi Zeng Yudong Ling Xiaojiang Chen Chao Ding Yukai Jin Shoucheng Feng Zhenchong Chen Jianrong Guo Haibo Qiu Source Type: research
CX ‑5461 potentiates imatinib‑induced apoptosis in K562 cells by stimulating < em > KIF1B < /em > expression
In conclusion, the results suggested that the synergistic interaction between CX-5461 and imatinib may be of potential clinical value for the treatment of tyrosine kinase inhibitor-resistant chronic myeloid leukemia.PMID:38356673 | PMC:PMC10865453 | DOI:10.3892/etm.2024.12395 (Source: Experimental and Therapeutic Medicine)
Source: Experimental and Therapeutic Medicine - February 15, 2024 Category: General Medicine Authors: Chaochao Dai Xiaopei Cui Jie Wang Bo Dong Haiqing Gao Mei Cheng Fan Jiang Source Type: research
